Quick Answer
LIPELLA PHARMACEUTICALS INC. reported R&D Expense of $3.61 million for fiscal year 2024.
LIPELLA PHARMACEUTICALS INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $3.61M | +18.9% |
| 2023 | $3.04M | +19.3% |
| 2022 | $2.55M | +74.9% |
| 2021 | $1.46M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $721.0K | -31.1% | -8.9% |
| June 30, 2025 | $791.6K | +19.7% | -20.3% |
| March 31, 2025 | $993.5K | +17.9% | -5.1% |
| September 30, 2024 | $1.05M | +25.6% | +58.2% |
| June 30, 2024 | $661.6K | -37.4% | -21.5% |
| March 31, 2024 | $842.6K | +21.5% | +1.1% |
| September 30, 2023 | $833.3K | +28.0% | -21.2% |
| June 30, 2023 | $1.06M | +42.4% | +52.5% |
- LIPELLA PHARMACEUTICALS INC. showed an increase of +18.9% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2024 period, LIPELLA PHARMACEUTICALS INC.’s r&d expense has grown by 148.0% (from $1.46 million to $3.61 million).
- The most recent figure is from LIPELLA PHARMACEUTICALS INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: